COVID-19 and immune protection – should we aim for elimination?
Part of regular seminar series of interest to mathematical and statistical modellers, and infectious disease epidemiologists.
Stay updated with breaking news from Deborah Cromer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Part of regular seminar series of interest to mathematical and statistical modellers, and infectious disease epidemiologists.
Newer variant-specific bivalent vaccines offer on average 1.6 times better immunity against COVID-19 than the original, single-strain ‘ancestral’ vaccines, new research by UNSW’s Kirby institute published today in Nature Medicine shows."We’re in an i
Australia’s newest vaccine targets a variant that is no longer being detected here. The US is further ahead because it has a different approach to approvals.
COVID-19 reinfections do occur - here is what you need to know.
As the COVID-19 pandemic continues to unfold, a key piece of information for informing public health decision making is how immune the population is over time and to the latest variants. An immune marker which correlates with immunity/vaccine efficacy, such as that used for influenza, is critical for public health decision making.